BOSTON, Nov. 11, 2021 /PRNewswire/ -- Ginkgo
Bioworks (NYSE: DNA), the leading horizontal platform for cell
programming, today announced the launch of its Cell Development
Kits (CDKs) service. CDKs provide streamlined access to the
company's platform for aspiring cell developers to program cells to
tackle the biggest challenges facing society. The first CDKs to
launch are focused on protein expression programs. The service
provides developers access to the toolkit needed to get started
developing commercial proteins, including pre-engineered host cells
optimized for protein production, specialized equipment, automation
capabilities, genetic engineering expertise, insights garnered from
Ginkgo's codebase and the applicable infrastructure to design,
build and test a custom microbe.
Ginkgo's CDKs are designed to cut the cost of launching a cell
program and speed up development timelines to build engineered
microbes, for example, to determine whether a protein may be
successfully and commercially produced. The service is also
designed to enable customers to prototype their idea in phases,
with each phase providing data that can inform the customer's
project and business strategy. By simplifying the pathway for
companies to get started on the Ginkgo platform with standard
terms, a phased approach, low costs—starting at $100,000 for protein expression projects—and
clear deliverables, the CDK can help derisk projects prior to full
scale technical development.
"We believe engineering biology holds tremendous potential to
revolutionize industries and our customers are using it to develop
solutions ranging from alternative food proteins and vaccine
ingredients to biodegradable plastics and sustainable chemicals,"
said Jason Kelly, CEO of Ginkgo
Bioworks. "But biology is still complex and highly variable, making
the barrier to entry too high for many of the product developers
that are out there with an idea they want to bring to the world. By
providing these researchers, entrepreneurs and dreamers with the
resources to realize their proof of concept, we're able to support
the synthetic biology ecosystem to keep pushing the envelope on
innovation."
If you are a developer interested in learning more about being
in the next batch of CDK projects to launch, reach out to the
Ginkgo team. Ginkgo will also be hosting an informational virtual
event, Grow with Ginkgo: You're a Cell Developer, for
prospective cell developers that are interested in learning more
about the CDK on Thursday, Nov. 11
from 10 a.m.-12 p.m. ET.
About Ginkgo Bioworks
Ginkgo is building a platform to
enable customers to program cells as easily as we can program
computers. The company's platform is enabling biotechnology
applications across diverse markets, from food and agriculture to
industrial chemicals to pharmaceuticals. Ginkgo has also actively
supported a number of COVID-19 response efforts, including K-12
pooled testing, vaccine manufacturing optimization and therapeutics
discovery. For more information, visit www.ginkgobioworks.com.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the launch and potential benefits of Ginkgo's
"Cell Development Kits" (CDKs) service and the potential of
Ginkgo's cell programming platform generally. These forward-looking
statements generally are identified by the words "believe,"
"project," "potential," "expect," "anticipate," "estimate,"
"intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely
result," and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including but not
limited to: (i) the effect of the business combination with Soaring
Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business
relationships, performance, and business generally, (ii) risks that
the business combination disrupts current plans of Ginkgo and
potential difficulties in Ginkgo's employee retention, (iii) the
outcome of any legal proceedings that may be instituted against
Ginkgo related to its business combination with Soaring Eagle, (iv)
volatility in the price of Ginkgo's securities now that it is a
public company due to a variety of factors, including changes in
the competitive and highly regulated industries in which Ginkgo
plans to operate, variations in performance across competitors,
changes in laws and regulations affecting Ginkgo's business and
changes in the combined capital structure, (v) the ability to
implement business plans, forecasts, and other expectations after
the completion of the business combination, and identify and
realize additional opportunities, and (vi) the risk of downturns in
demand for products using synthetic biology. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the "Risk Factors" section of Ginkgo's current report on Form
8-K filed with the U.S. Securities and Exchange Commission (the
"SEC") on September 20, 2021 and
other documents filed by Ginkgo from time to time with the SEC.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Ginkgo assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Ginkgo does
not give any assurance that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-launches-cell-development-kit-service-for-standardized-low-cost-entry-to-its-cell-programming-platform-301421988.html
SOURCE Ginkgo Bioworks